Global Adeno-Associated Virus Vector-Based Gene Therapy Market Report and Forecast 2023-2031

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Report and Forecast 2023-2031

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Outlook

The global adeno-associated virus (AAV) vector-based gene therapy market is expected to witness significant growth during the forecast period of 2023-2031, driven by the rising prevalence of genetic disorders and the increasing investments in research and development activities. The market is projected to grow at a CAGR of 18.5% during the forecast period.

Adeno-Associated Virus Vector-Based Gene Therapy Market: Introduction

The global adeno-associated virus (AAV) vector-based gene therapy market report by Expert Market Research provides an in-depth analysis of the market and its segments. AAV is a non-pathogenic virus that is used as a delivery vehicle for therapeutic genes to treat genetic disorders. The report covers the market for AAV vector-based gene therapy and provides a detailed analysis of the market size, growth, and trends.

The AAV vector-based gene therapy market is expected to witness significant growth in the coming years due to the increasing prevalence of genetic disorders and the rising demand for innovative treatment options. The development of advanced technologies, such as genome editing and gene silencing, is expected to further drive the growth of the market. Additionally, the increasing focus on precision medicine and personalized treatment options is likely to create lucrative opportunities for the market players.

Furthermore, the increasing investments in research and development activities, coupled with the growing number of clinical trials, are expected to fuel the growth of the market. The adoption of advanced healthcare infrastructure and the increasing demand for better healthcare services in emerging economies are expected to further contribute to the growth of the market.

Adeno-Associated Virus Vector-Based Gene Therapy Market Segmentations

The market can be categorised into therapeutic agents, indication type, and treatment channel.

Market Breakup by Therapeutic AgentsCorticosteroid DrugsImmunosuppressive DrugsACE Inhibitors and ARBsOthersMarket Breakup by Indication TypeHaematological DisordersHaemophilia AHaemophilia BOphthalmological DisordersChloridaemiaRetinitis PigmentosaLysosomal Storage DisordersFabry DiseasePompe DiseaseHunter SyndromeNeurological DisordersParkinson's DiseaseBatten DiseaseMusculoskeletal DisordersDuchenne Muscular Dystrophy (DMD)Spinal Muscular Atrophy (SMA)Market Breakup by Treatment ChannelPublicPrivateMarket Breakup by Region North America United States of America Canada Europe United Kingdom Germany France Italy Others Asia Pacific China Japan India ASEAN Australia Others Latin America Brazil Argentina Mexico Others Middle East and AfricaSaudi Arabia United Arab Emirates Nigeria South Africa Others Adeno-Associated Virus Vector-Based Gene Therapy Market Scenario

The global adeno -Associated Virus (AAV) vector-based gene therapy market is expected to witness significant growth during the forecast period of 2023-2031. North America dominates the market, followed by Europe and Asia Pacific. The high prevalence of genetic disorders in North America, coupled with the favorable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for AAV vector-based gene therapy, with the presence of key players and increasing investments in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of genetic disorders and rising healthcare expenditure in the region.

Key Players in the Global Adeno-Associated Virus Vector-Based Gene Therapy Market

The report gives an in-depth analysis of the key players involved in the adeno-associated virus vector-based gene therapy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:Arya Sciences Acquisition Corp.Pfizer Inc.Roche Holding AGBioMarin Pharmaceutical Inc.Bayer AGCoave TherapeuticsMeiraGTx LimitedNeurocrine Biosciences, Inc.Biogen, Inc.Sangamo TherapeuticsSarepta Therapeutics, Inc.